Clinical evaluation of rush immunotherapy using house dust mite allergen in Japanese asthmatics.
Takahiro UchidaKazuyuki NakagomeHidetoshi IemuraErika NaitoSachiko MiyauchiYoshitaka UchidaTomoyuki SomaMakoto NagataPublished in: Asia Pacific allergy (2021)
Rush-HDM-IT can be performed relatively safely in Japanese asthmatics. Furthermore, rush-HDM-IT and the subsequent maintenance SCIT provided clinical improvement in asthma patients, and was accompanied by the suppression of HDM-specific Th2-mediated systemic immune responses.
Keyphrases
- clinical evaluation
- end stage renal disease
- immune response
- allergic rhinitis
- chronic kidney disease
- newly diagnosed
- ejection fraction
- chronic obstructive pulmonary disease
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- toll like receptor
- lung function
- health risk
- cystic fibrosis
- heavy metals
- air pollution
- health risk assessment